0001610717-23-000291.txt : 20230920
0001610717-23-000291.hdr.sgml : 20230920
20230920062308
ACCESSION NUMBER: 0001610717-23-000291
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230919
FILED AS OF DATE: 20230920
DATE AS OF CHANGE: 20230920
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Burow Kristina
CENTRAL INDEX KEY: 0001569248
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41802
FILM NUMBER: 231265267
MAIL ADDRESS:
STREET 1: 8755 W. HIGGINS ROAD
STREET 2: SUITE 1025
CITY: CHICAGO
STATE: IL
ZIP: 60631
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Neumora Therapeutics, Inc.
CENTRAL INDEX KEY: 0001885522
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 844367680
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 490 ARSENAL WAY, SUITE 200
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: (857) 760-0900
MAIL ADDRESS:
STREET 1: 490 ARSENAL WAY, SUITE 200
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: RBNC Therapeutics, Inc.
DATE OF NAME CHANGE: 20210929
4
1
form4.xml
X0508
4
2023-09-19
0001885522
Neumora Therapeutics, Inc.
NMRA
0001569248
Burow Kristina
C/O NEUMORA THERAPEUTICS, INC.
490 ARSENAL WAY, SUITE 200
WATERTOWN
MA
02472
true
true
false
Common Stock
2023-09-19
4
C
0
13620
A
13620
D
Common Stock
2023-09-19
4
C
0
684167
A
684167
I
See Footnotes
Common Stock
2023-09-19
4
C
0
1144973
A
1144973
I
See Footnotes
Common Stock
2023-09-19
4
C
0
6895021
A
12205379
I
See Footnotes
Common Stock
2023-09-19
4
C
0
6576400
A
11886758
I
See Footnotes
Common Stock
2023-09-19
4
C
0
2124143
A
2124143
I
See Footnote
Common Stock
2023-09-19
4
P
0
1500000
17
A
3624143
I
See Footnote
Series A-1 Preferred Stock
2023-09-19
4
C
0
13620
D
Common Stock
13620
0
D
Series A-1 Preferred Stock
2023-09-19
4
C
0
684167
D
Common Stock
684167
0
I
See Footnotes
Series A-1 Preferred Stock
2023-09-19
4
C
0
1144973
D
Common Stock
1144973
0
I
See Footnotes
Series A-2 Preferred Stock
2023-09-19
4
C
0
6895021
D
Common Stock
6895021
0
I
See Footnotes
Series A-2 Preferred Stock
2023-09-19
4
C
0
6576400
D
Common Stock
6576400
0
I
See Footnotes
Series B Preferred Stock
2023-09-19
4
C
0
2124143
D
Common Stock
2124143
0
I
See Footnote
The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.
Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. AVP VII LLC Managing Directors each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. The Reporting Person is a managing director at AVP VII LLC and owns an interest in AVP VII LP but does not have voting or investment control over the shares held by ARCH VII.
Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. AVP VIII LLC Managing Directors each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. The Reporting Person is a managing director at AVP VIII LLC and owns an interest in AVP VIII LLC but does not have voting or investment control over the shares held by ARCH VIII Overage.
The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X Committee Members each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any.
Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. AVP XII LLC Committee Members each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any.
/s/ Joshua Pinto, as Attorney-in-Fact for Kristina M. Burow
2023-09-19